Humana price target lowered to $560 from $580 at Truist

Truist analyst David MacDonald lowered the firm’s price target on Humana to $560 from $580 and keeps a Hold rating on the shares after its Q4 results and guidance. The firm is raising its 2023 and 2024 adjusted EPS estimates by 19c and 12c to $28.04 and $31.70 respectively but reduced its price target to reflect a rate environment that is expected to be more modest.